Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial

Abstract CT157: Treatment beyond progression with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck in the phase 3 Checkmate 141 study

10.1158/1538-7445.am2017-ct157 ◽

2017 ◽

Cited By ~ 3

Author(s):

Robert Haddad ◽

Robert L. Ferris ◽

George Blumenschein ◽

Jerome Fayette ◽

Joel Guigay ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Phase 3 ◽

Treatment Beyond Progression ◽

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(11)70034-1 ◽

2011 ◽

Vol 12 (4) ◽

pp. 333-343 ◽

Cited By ~ 165

Author(s):

Jean-Pascal Machiels ◽

Somasundaram Subramanian ◽

Agnes Ruzsa ◽

Gabor Repassy ◽

Igor Lifirenko ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Supportive Care ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Best Supportive Care ◽

Open Label ◽

Phase 3 ◽

Platinum Based Chemotherapy ◽

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)70124-5 ◽

2015 ◽

Vol 16 (5) ◽

pp. 583-594 ◽

Cited By ~ 239

Author(s):

Jean-Pascal H Machiels ◽

Robert I Haddad ◽

Jérôme Fayette ◽

Lisa F Licitra ◽

Makoto Tahara ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Line Treatment ◽

Second Line ◽

Open Label ◽

Phase 3 ◽

Head Neck

Faculty of 1000 evaluation for Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718018463.793480272 ◽

2013 ◽

Author(s):

Sandra Nuyts

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Randomised Trial ◽

Open Label ◽

Phase 3 ◽

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70181-5 ◽

2013 ◽

Vol 14 (8) ◽

pp. 697-710 ◽

Cited By ~ 301

Author(s):

Jan B Vermorken ◽

Jan Stöhlmacher-Williams ◽

Irina Davidenko ◽

Lisa Licitra ◽

Eric Winquist ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Randomised Trial ◽

Open Label ◽

Phase 3 ◽

A phase I/II clinical trial of sorafenib in combination with cisplatin and docetaxel in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps6103 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS6103-TPS6103

Author(s):

Panayiotis Savvides ◽

Pawan Kumar ◽

Maura L. Gillison ◽

Ted Teknos

Keyword(s):

Clinical Trial ◽

Squamous Cell Carcinoma ◽

Phase I ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Faculty Opinions recommendation of Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718018463.793481234 ◽

2013 ◽

Author(s):

Bruce Brockstein ◽

Nicholas Campbell

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Randomised Trial ◽

Open Label ◽

Phase 3 ◽

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

The Lancet ◽

10.1016/s0140-6736(19)32591-7 ◽

2019 ◽

Vol 394 (10212) ◽

pp. 1915-1928 ◽

Cited By ~ 230

Author(s):

Barbara Burtness ◽

Kevin J Harrington ◽

Richard Greil ◽

Denis Soulières ◽

Makoto Tahara ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Open Label ◽

Phase 3 ◽

Faculty Opinions recommendation of Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.14264023.15777137 ◽

2012 ◽

Author(s):

Marco Merlano

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Clinical Activity ◽

Molecular Response ◽

Faculty Opinions recommendation of Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): a trial of the Eastern Cooperative Oncology Group.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717954085.793459863 ◽

2012 ◽

Author(s):

Marco Merlano

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Proteasome Inhibitor ◽

Eastern Cooperative Oncology Group ◽

Oncology Group ◽

Locally Recurrent